Volume 96, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In Cusco, Peru, and South America in general, there is a dearth of travelers' diarrhea (TD) data concerning the clinical features associated with enteropathogen-specific infections and destination-specific risk behaviors. Understanding these factors would allow travel medicine providers to tailor interventions to patients' risk profiles and travel destination. To characterize TD etiology, evaluate region-specific TD risk factors, and examine relationships between preventive recommendations and risk-taking behaviors among medium- to long-term travelers' from high-income countries, we conducted this case–case analysis using 7 years of prospective surveillance data from adult travelers' presenting with TD to a physician in Cusco. At the time of enrollment, participants provided a stool sample and answered survey questions about demographics, risk behaviors, and the clinical features of illness. Stool samples were tested for norovirus (NV), bacteria, and parasites using conventional methods. Data obtained were then analyzed using case–case methods. NV (14%), enterotoxigenic (11%), and (9%), notably ciprofloxacin-resistant , were the most frequently identified pathogens among adults with TD. Coinfection with multiple enteropathogens occurred in 5% of cases. NV caused severe disease relative to other TD-associated pathogens identified, confining over 90% of infected individuals to bed. Destination-specific risk factors include consumption of the local beverage “chicha,” which was associated with infection. Preventive interventions, such as vaccines, directed against these pathogens could significantly reduce the burden of TD.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. Cabada MM, Maldonado F, Quispe W, Mozo K, Serrano E, Gonzalez E, Seas C, Verdonck K, Echevarria JI, Dupont HL, Gotuzzo E, , 2006. Risk factors associated with diarrhea among international visitors to Cuzco, Peru. Am J Trop Med Hyg 75: 968972.
  2. Cabada MM, White AC, Jr, 2008. Travelers' diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep 10: 473479.[Crossref]
  3. Cabada MM, Maldonado F, Quispe W, Serrano E, Mozo K, Gonzales E, Seas C, Verdonck K, Echevarria JI, Gotuzzo E, , 2005. Pretravel health advice among international travelers visiting Cuzco, Peru. J Travel Med 12: 6165.[Crossref]
  4. Cabada MM, Maldonado F, Mozo K, Dziuba N, Gotuzzo E, , 2010. Pre-travel preparation for Cusco, Peru: a comparison between European and North American travelers. J Travel Med 17: 382386.[Crossref]
  5. Steffen R, Hill DR, DuPont HL, , 2015. Traveler's diarrhea: a clinical review. JAMA 313: 7180.[Crossref]
  6. Hill DR, , 2000. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg 62: 585589.
  7. Shlim DR, , 2005. Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin Infect Dis 41 (Suppl 8): S531S535.[Crossref]
  8. Steffen R, , 2005. Epidemiology of traveler's diarrhea. Clin Infect Dis 41 (Suppl 8): S536S540.[Crossref]
  9. Patel RR, Liang SY, Koolwal P, Kuhlmann FM, , 2015. Travel advice for the immunocompromised traveler: prophylaxis, vaccination, and other preventive measures. Ther Clin Risk Manag 11: 217228.
  10. Hill DR, Beeching NJ, , 2010. Travelers' diarrhea. Curr Opin Infect Dis 23: 481487.[Crossref]
  11. McCarthy N, Giesecke J, , 1999. Case-case comparisons to study causation of common infectious diseases. Int J Epidemiol 28: 764768.[Crossref]
  12. Potoski BA, Adams J, Clarke L, Shutt K, Linden PK, Baxter C, Pasculle AW, Capitano B, Peleg AY, Szabo D, Paterson DL, , 2006. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 43: 165171.[Crossref]
  13. Varga C, Middleton D, Walton R, Savage R, Tighe MK, Allen V, Ahmed R, Rosella L, , 2012. Evaluating risk factors for endemic human Salmonella enteritidis infections with different phage types in Ontario, Canada using multinomial logistic regression and a case-case study approach. BMC Public Health 12: 866.[Crossref]
  14. Krumkamp R, Reintjes R, Dirksen-Fischer M, , 2008. Case-case study of a Salmonella outbreak: an epidemiologic method to analyse surveillance data. Int J Hyg Environ Health 211: 163167.[Crossref]
  15. Ericsson CD, , 1998. Travelers' diarrhea: epidemiology, prevention, and self-treatment. Infect Dis Clin North Am 12: 285303.[Crossref]
  16. Shah N, DuPont HL, Ramsey DJ, , 2009. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 80: 609614.
  17. Zaidi D, Wine E, , 2015. An update on travelers' diarrhea. Curr Opin Gastroenterol 31: 713.[Crossref]
  18. Ritchie LS, , 1948. An ether sedimentation technique for routine stool examinations. Bull US Army Med Dep 8: 326.
  19. Gray L, Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, , 1995. Escherichia, Salmonella, Shigella, and Yersinia . , eds. Manual of Clinical Microbiology. Washington, DC: ASM Press.
  20. Nachamkin I, Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, , 1999. Campylobacter and Arcobacter . , eds. Manual of Clinical Microbiology. Washington, DC: ASM Press, 716726.
  21. Stacy-Phipps S, Mecca JJ, Weiss JB, , 1995. Multiplex PCR assay and simple preparation method for stool specimens detect enterotoxigenic Escherichia coli DNA during course of infection. J Clin Microbiol 33: 10541059.
  22. Clinical and Laboratory Standards Institute (CLSI), 2011. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. M100-S21. Wayne, PA: CLSI.
  23. Ochoa TJ, Ruiz J, Molina M, Del Valle LJ, Vargas M, Gil AI, Ecker L, Barletta F, Hall E, Cleary TG, Lanata CF, , 2009. High frequency of antimicrobial drug resistance of diarrheagenic Escherichia coli in infants in Peru. Am J Trop Med Hyg 81: 296301.
  24. Medina AM, Rivera FP, Pons MJ, Riveros M, Gomes C, Bernal M, Meza R, Maves RC, Huicho L, Chea-Woo E, Lanata CF, Gil AI, Ochoa TJ, Ruiz J, , 2015. Comparative analysis of antimicrobial resistance in enterotoxigenic Escherichia coli isolates from two paediatric cohort studies in Lima, Peru. Trans R Soc Trop Med Hyg 109: 493502.[Crossref]
  25. Fass RJ, , 1993. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 37: 20802086.[Crossref]
  26. Howie RL, Folster JP, Bowen A, Barzilay EJ, Whichard JM, , 2010. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist 16: 245248.[Crossref]
  27. Sjolund-Karlsson M, Joyce K, Blickenstaff K, Ball T, Haro J, Medalla FM, Fedorka-Cray P, Zhao S, Crump JA, Whichard JM, , 2011. Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States. Antimicrob Agents Chemother 55: 39853989.[Crossref]
  28. Crump JA, Sjolund-Karlsson M, Gordon MA, Parry CM, , 2015. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev 28: 901937.[Crossref]
  29. Apaza S, Espetia S, Gilman RH, Montenegro S, Pineda S, Herhold F, Pomari R, Kosek M, Vu N, Saito M, , 2012. Detection and genogrouping of noroviruses from children's stools by Taqman one-step RT-PCR. J Vis Exp 65: e3232.
  30. Wilson N, Baker M, Edwards R, Simmons G, , 2008. Case-case analysis of enteric diseases with routine surveillance data: potential use and example results. Epidemiol Perspect Innov 5: 6.[Crossref]
  31. Lalani T, Maguire JD, Grant EM, Fraser J, Ganesan A, Johnson MD, Deiss RG, Riddle MS, Burgess T, Tribble DR, IDCRP TravMil Study Group; , 2015. Epidemiology and self-treatment of travelers' diarrhea in a large, prospective cohort of department of defense beneficiaries. J Travel Med 22: 152160.[Crossref]
  32. Jelinek T, Kollaritsch H, , 2008. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. Expert Rev Vaccines 7: 561567.[Crossref]
  33. Ballard SB, Saito M, Mirelman AJ, Bern C, Gilman RH, , 2015. Tropical and travel-associated norovirus: current concepts. Curr Opin Infect Dis 28: 408416.[Crossref]
  34. Pires SM, Fischer-Walker CL, Lanata CF, Devleesschauwer B, Hall AJ, Kirk MD, Duarte AS, Black RE, Angulo FJ, , 2015. Aetiology-specific estimates of the global and regional incidence and mortality of diarrhoeal diseases commonly transmitted through food. PLoS One 10: e0142927.[Crossref]
  35. Cabada MM, Okhuysen PC, White AC, Jr, 2013. Enteropathogens and chronic illness in returning travelers. N Engl J Med 369: 783.[Crossref]
  36. Gonzaga VE, Ramos M, Maves RC, Freeman R, Montgomery JM, , 2011. Concurrent outbreak of norovirus genotype I and enterotoxigenic Escherichia coli on a U.S. navy ship following a visit to Lima, Peru. PLoS One 6: e20822.[Crossref]
  37. Karst SM, Wobus CE, Goodfellow IG, Green KY, Virgin HW, , 2014. Advances in norovirus biology. Cell Host Microbe 15: 668680.[Crossref]
  38. Saito M, Goel-Apaza S, Espetia S, Velasquez D, Cabrera L, Loli S, Crabtree JE, Black RE, Kosek M, Checkley W, Zimic M, Bern C, Cama V, Gilman RH, Norovirus Working Group in Peru; , 2014. Multiple norovirus infections in a birth cohort in a Peruvian periurban community. Clin Infect Dis 58: 483491.[Crossref]
  39. Donowitz JR, Alam M, Kabir M, Ma JZ, Nazib F, Platts-Mills JA, Bartelt LA, Haque R, Petri WA, Jr, 2016. A prospective longitudinal cohort to investigate the effects of early life giardiasis on growth and all cause diarrhea. Clin Infect Dis 63: 792797.[Crossref]
  40. Hanevik K, , 2016. Editorial commentary: Giardia lamblia—pathogen or commensal? Clin Infect Dis 63: 798799.[Crossref]
  41. DuPont HL, , 2013. Giardia: both a harmless commensal and a devastating pathogen. J Clin Invest 123: 23522354.[Crossref]
  42. Ballard SB, Reaves EJ, Luna CG, Silva ME, Rocha C, Heitzinger K, Saito M, Apaza S, Espetia S, Blazes DL, Tilley DH, Guzman Aguilar RC, Gilman RH, Bausch DG, , 2015. Epidemiology and genetic characterization of noroviruses among adults in an endemic setting, Peruvian Amazon basin, 2004–2011. PLoS One 10: e0131646.[Crossref]
  43. Tallant A, Porter CK, Putnam SD, Tribble DR, Hooper TI, Riddle MS, , 2014. Relative cost-effectiveness of a norovirus vaccine in the deployed military setting compared to a vaccine against Campylobacter sp., ETEC, and Shigella sp. Vaccine 32: 51565162.[Crossref]
  44. Pollett S, Rocha C, Zerpa R, Patino L, Valencia A, Camina M, Guevara J, Lopez M, Chuquiray N, Salazar-Lindo E, Calampa C, Casapia M, Meza R, Bernal M, Tilley D, Gregory M, Maves R, Hall E, Jones F, Arriola CS, Rosenbaum M, Perez J, Kasper M, , 2012. Campylobacter antimicrobial resistance in Peru: a ten-year observational study. BMC Infect Dis 12: 193.[Crossref]
  45. U.S. Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, 2014. Enterotoxigenic E. coli (ETEC). Available at: http://www.cdc.gov/ecoli/etec.html.

Data & Media loading...

  • Received : 02 Aug 2016
  • Accepted : 22 Nov 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error